Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
TNGX · Why this verdict
Why Tango Therapeutics (TNGX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Tango Therapeutics is a clinical-stage biotechnology company whose investment case rests almost entirely on the progress of a single drug candidate, vopimetostat, while the company burns cash at a rate exceeding revenues and carries a high short interest of 23%. Positive price momentum and strong analyst upside of 23% offer a counter-narrative, but the quality floor failure and binary pipeline risk make this a speculative holding.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The entire commercial value of Tango Therapeutics is concentrated in vopimetostat, as identified in the risk data, meaning any clinical setback or regulatory delay would likely destroy most of the current market valuation. Bear case | Vopimetostat advances to a later-stage trial milestone within 12 months without a clinical hold or material dose-limiting toxicity signal. | →Stable |
| CounterPipeline concentration is endemic to small biotechs; many single-asset companies still generate strong returns when the lead candidate succeeds, and the put-to-call ratio of 0.317 suggests options market participants lean bullish. | ||
The company's free cash flow stands at negative 120% of revenue and its quality score of 1.7 is below the minimum investment threshold of 4.0, indicating that the business is in a heavy spend phase with no self-funding capacity. Quality breakdown | Cash runway remains sufficient for at least 12 months of operations without a dilutive equity raise exceeding 10% of shares outstanding. | →Stable |
| CounterCash burn is expected for pre-revenue biotechs; the current ratio of 5.0 suggests near-term liquidity is adequate, and a high burn rate may simply reflect accelerating investment in clinical activity. | ||
A short interest of 23% of float signals that a significant portion of the market is betting against the company, creating both a risk of continued price pressure and a potential short-squeeze catalyst if positive data emerges. Risk breakdown | Short interest declines below 15% within 12 months as clinical progress reduces binary risk perception. | →Stable |
| CounterHigh short interest in small biotechs often persists through trials and may reflect sophisticated institutional analysis of pipeline weakness rather than an exploitable contrarian signal. | ||
Despite weak fundamentals, the stock trades above its 200-day moving average with rising volume accumulation and an RSI of 74, suggesting near-term buying interest that may be driven by anticipation of upcoming clinical data. Momentum breakdown | Price remains above the 200-day moving average and OBV stays positive over the next 6 months. | →Stable |
| CounterAn RSI of 74 is overbought territory, and a momentum score of 6.9 in a pre-revenue biotech can reverse sharply on any negative clinical or regulatory update. | ||
The entire commercial value of Tango Therapeutics is concentrated in vopimetostat, as identified in the risk data, meaning any clinical setback or regulatory delay would likely destroy most of the current market valuation.
→StableBear case
- Expectation
- Vopimetostat advances to a later-stage trial milestone within 12 months without a clinical hold or material dose-limiting toxicity signal.
CounterPipeline concentration is endemic to small biotechs; many single-asset companies still generate strong returns when the lead candidate succeeds, and the put-to-call ratio of 0.317 suggests options market participants lean bullish.
The company's free cash flow stands at negative 120% of revenue and its quality score of 1.7 is below the minimum investment threshold of 4.0, indicating that the business is in a heavy spend phase with no self-funding capacity.
→StableQuality breakdown
- Expectation
- Cash runway remains sufficient for at least 12 months of operations without a dilutive equity raise exceeding 10% of shares outstanding.
CounterCash burn is expected for pre-revenue biotechs; the current ratio of 5.0 suggests near-term liquidity is adequate, and a high burn rate may simply reflect accelerating investment in clinical activity.
A short interest of 23% of float signals that a significant portion of the market is betting against the company, creating both a risk of continued price pressure and a potential short-squeeze catalyst if positive data emerges.
→StableRisk breakdown
- Expectation
- Short interest declines below 15% within 12 months as clinical progress reduces binary risk perception.
CounterHigh short interest in small biotechs often persists through trials and may reflect sophisticated institutional analysis of pipeline weakness rather than an exploitable contrarian signal.
Despite weak fundamentals, the stock trades above its 200-day moving average with rising volume accumulation and an RSI of 74, suggesting near-term buying interest that may be driven by anticipation of upcoming clinical data.
→StableMomentum breakdown
- Expectation
- Price remains above the 200-day moving average and OBV stays positive over the next 6 months.
CounterAn RSI of 74 is overbought territory, and a momentum score of 6.9 in a pre-revenue biotech can reverse sharply on any negative clinical or regulatory update.
Per-dimension breakdown
Quality
1.7/10data confidence 86%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -120% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 3.8 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.3 |
| Price target | 8.8 |
| erm sentiment | 3.4 |
- ▸Analyst upside: 33%
Insider
4.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.7 |
- ▸Modest insider selling — $2,724,647 (0.057% of mkt cap)
Peer rank
1.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.1 |
| quality rank | 1.9 |
| growth rank | 5.0 |
Technical
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.2 |
| support resistance | 2.7 |
| 52w position | 7.7 |
Risk (lower is worse)
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.2 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 7.7 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 6.2 |
| debt equity | 0.0 |
- ▸High short interest justified: 23%
- ▸High IV: 90%
- ▸Above max pain $1
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 3.5 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:5.6>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.1<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.05
Upside
+15.7%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $4.7B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.1<1.5@spot.
The strongest dimensions are Value at 7.5, Sentiment at 7.1, and Catalyst at 6.0; the weakest are Quality at 1.7, Peer rank at 1.9, and Risk (lower is worse) at 2.3. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.05 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The entire commercial value of Tango Therapeutics is concentrated in vopimetostat, as identified in the risk data, meaning any clinical setback or regulatory delay would likely destroy most of the current market valuation.
Trip ifPrice drops below $27, more than 18% below the current $32.90, following a clinical hold, dose-limiting toxicity announcement, or trial discontinuation.
- P2The company's free cash flow stands at negative 120% of revenue and its quality score of 1.7 is below the minimum investment threshold of 4.0, indicating that the business is in a heavy spend phase with no self-funding capacity.
Trip ifA dilutive equity offering exceeds 10% of shares outstanding, or cash balance falls below a level sufficient to fund more than 6 months of operations at the current burn rate.
- P3A short interest of 23% of float signals that a significant portion of the market is betting against the company, creating both a risk of continued price pressure and a potential short-squeeze catalyst if positive data emerges.
Trip ifShort interest rises above 30% of float, indicating increased institutional conviction that the pipeline will fail.
- P4Despite weak fundamentals, the stock trades above its 200-day moving average with rising volume accumulation and an RSI of 74, suggesting near-term buying interest that may be driven by anticipation of upcoming clinical data.
Trip ifPrice falls below the 200-day moving average for more than 20 consecutive trading days, signaling momentum exhaustion.